StockNews.com started coverage on shares of Second Sight Medical Products (NASDAQ:EYES – Get Rating) in a research report report published on Saturday morning. The brokerage issued a sell rating on the medical device company's stock.

Second Sight Medical Products Stock Performance

The business has a fifty day simple moving average of $5.80 and a 200 day simple moving average of $5.21. Second Sight Medical Products has a 12 month low of $3.42 and a 12 month high of $12.72.

Hedge Funds Weigh In On Second Sight Medical Products

Institutional investors and hedge funds have recently modified their holdings of the company. Jane Street Group LLC lifted its position in Second Sight Medical Products by 111.8% in the second quarter. Jane Street Group LLC now owns 21,601 shares of the medical device company's stock valued at $44,000 after acquiring an additional 11,403 shares during the last quarter. Virtu Financial LLC increased its stake in shares of Second Sight Medical Products by 130.6% during the second quarter. Virtu Financial LLC now owns 31,258 shares of the medical device company's stock worth $63,000 after acquiring an additional 17,703 shares during the period. Millennium Management LLC acquired a new position in shares of Second Sight Medical Products during the second quarter worth about $207,000. Renaissance Technologies LLC acquired a new position in shares of Second Sight Medical Products during the first quarter worth about $249,000. Finally, Vanguard Group Inc. grew its position in Second Sight Medical Products by 1.4% during the first quarter. Vanguard Group Inc. now owns 1,221,704 shares of the medical device company's stock worth $1,747,000 after buying an additional 17,164 shares during the period.

About Second Sight Medical Products

Second Sight Medical Products, Inc develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury.

See Also

• Get a free copy of the StockNews.com research report on Second Sight Medical Products (EYES)
• Roku Stock is Down but Not Out
• Is Ford Rolling To A Rebound After Its Q3 Warning
• If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
• Has AMD stock stock fallen too far?
• Oracle's Short-Term Pain Could Be Your Long-Term Gain

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.